{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:58:35Z","timestamp":1758970715077,"version":"3.40.3"},"reference-count":97,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiology &amp; Behavior"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.physbeh.2012.06.023","type":"journal-article","created":{"date-parts":[[2012,7,7]],"date-time":"2012-07-07T02:51:33Z","timestamp":1341629493000},"page":"801-808","source":"Crossref","is-referenced-by-count":14,"title":["Translating laboratory discovery to the clinic: From nicotine and mecamylamine to Tourette's, depression, and beyond"],"prefix":"10.1016","volume":"107","author":[{"given":"Paul R.","family":"Sanberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Vindrola-Padros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Douglas","family":"Shytle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.physbeh.2012.06.023_bb0005","series-title":"Motor activity and movement disorders: research issues and applications","article-title":"Clinical assessment of motor abnormalities in Tourette's syndrome","author":"Shytle","year":"1995"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0733-8619(05)70313-3","article-title":"The course and prognosis of Tourette syndrome","volume":"15","author":"Bruun","year":"1997","journal-title":"Neurol Clin"},{"issue":"Pt 3","key":"10.1016\/j.physbeh.2012.06.023_bb0015","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/brain\/123.3.425","article-title":"Tourette syndrome, associated conditions and the complexities of treatment","volume":"123","author":"Robertson","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0020","first-page":"804","article-title":"A controlled study of Tourette syndrome. V. Depression and mania","volume":"41","author":"Comings","year":"1987","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0025","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/archpsyc.1986.01800120063012","article-title":"Gilles de la Tourette's syndrome and attention deficit disorder with hyperactivity. Evidence against a genetic relationship","volume":"43","author":"Pauls","year":"1986","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0030","first-page":"113","article-title":"Neurobiology of basal ganglia circuits in Tourette syndrome: faulty inhibition of unwanted motor patterns?","volume":"85","author":"Mink","year":"2001","journal-title":"Adv Neurol"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0035","first-page":"1243","article-title":"D2-like dopamine receptor density in Tourette syndrome measured by PET","volume":"38","author":"Wong","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jns.2007.01.069","article-title":"Frontal dopaminergic abnormality in Tourette syndrome: a postmortem analysis","volume":"255","author":"Yoon","year":"2007","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0045","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/01.mnm.0000239485.53780.16","article-title":"Evaluating dopamine transporter activity with 99mTc-TRODAT-1 SPECT in drug-naive Tourette's adults","volume":"27","author":"Yeh","year":"2006","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0050","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pscychresns.2007.01.003","article-title":"Phasic dysfunction of dopamine transmission in Tourette's syndrome evaluated with 99mTc TRODAT-1 imaging","volume":"156","author":"Yeh","year":"2007","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0055","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/08830738060210080401","article-title":"Treatment of children and adolescents with tics and Tourette syndrome","volume":"21","author":"Gilbert","year":"2006","journal-title":"J Child Neurol"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0060","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0304-3940(88)90588-5","article-title":"D1- and D2-receptor antagonists induce catalepsy via different efferent striatal pathways [corrected]","volume":"85","author":"Ogren","year":"1988","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0065","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0091-3057(84)80060-X","article-title":"The role of the GABA mechanisms of the globus pallidus in mediating catalepsy, stereotypy and locomotor activity","volume":"21","author":"Ossowska","year":"1984","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0070","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/284472a0","article-title":"Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors","volume":"284","author":"Sanberg","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0075","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0091-3057(91)90256-2","article-title":"Nicotine potentiates haloperidol-induced catalepsy and locomotor hypoactivity","volume":"38","author":"Emerich","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0080","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(94)90388-3","article-title":"Longlasting improvement of Tourette's syndrome with transdermal nicotine","volume":"344","author":"Dursun","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0085","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1523\/JNEUROSCI.13-06-02680.1993","article-title":"Evidence for \u201cpreterminal\u201d nicotinic receptors on GABAergic axons in the rat interpeduncular nucleus","volume":"13","author":"Lena","year":"1993","journal-title":"J Neurosci"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0090","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-2236(93)90150-K","article-title":"Allosteric modulations of the nicotinic acetylcholine receptor","volume":"16","author":"Lena","year":"1993","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0095","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF00713026","article-title":"Desensitization of the nicotinic acetylcholine receptor: molecular mechanisms and effect of modulators","volume":"9","author":"Ochoa","year":"1989","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0022-3565(25)13332-6","article-title":"Effects of chronic administration of nicotine on prolactin release in the rat: inactivation of prolactin response by repeated injections of nicotine","volume":"252","author":"Hulihan-Giblin","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0105","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/0024-3205(89)90444-X","article-title":"Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders","volume":"44","author":"Moss","year":"1989","journal-title":"Life Sci"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0110","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1476-5381.1985.tb11081.x","article-title":"Electrophysiological actions of nicotine on substantia nigra single units","volume":"85","author":"Clarke","year":"1985","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0115","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(88)91388-8","article-title":"Nicotine gum and haloperidol in Tourette's syndrome [letter]","volume":"1","author":"Sanberg","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0753-3322(89)90186-8","article-title":"Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome","volume":"43","author":"Sanberg","year":"1989","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0125","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1176\/ajp.148.6.793","article-title":"Nicotine potentiation of haloperidol in reducing tic frequency in Tourette's disorder [published erratum appears in Am J Psychiatry 1991 Sep;148(9):1282] [see comments]","volume":"148","author":"McConville","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0130","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/0006-3223(92)90315-Q","article-title":"The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder","volume":"31","author":"McConville","year":"1992","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0135","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2165\/00003088-198712010-00003","article-title":"Clinical pharmacokinetics of nicotine","volume":"12","author":"Svensson","year":"1987","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0163-7258(96)00199-4","article-title":"Nicotine for the treatment of Tourette's syndrome","volume":"74","author":"Sanberg","year":"1997","journal-title":"Pharmacol Therapeut"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0145","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1017\/S1092852900011408","article-title":"Clinical experience with transdermal nicotine patch in Tourette syndrome","volume":"4","author":"Silver","year":"1999","journal-title":"CNS Spectr"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0150","unstructured":"Shytle, R., Baker, M., Silver, A., Soloman, M., Sanberg, P. Smoking, nicotine and movement disorders. In: Newhouse MPaP, ed. APA Clinical Practice Series. Halifax, Canada: APA Press; 2000. p. 183\u2013202."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0155","first-page":"35","article-title":"Nicotine as a therapeutic adjunct for Tourette's Syndrome. Nicotine as a therapeutic agent","author":"Sanberg","year":"1997","journal-title":"Immun Environ"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0160","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0140-6736(93)91392-Y","article-title":"Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome","volume":"342","author":"Silver","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0165","series-title":"The effects of nicotine on biological systems","first-page":"293","article-title":"Transdermal nicotine in Tourette's syndrome","author":"Silver","year":"1995"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0170","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/00004583-199612000-00015","article-title":"Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome","volume":"35","author":"Silver","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0175","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1017\/S1092852900011408","article-title":"Clinical experience with transdermal nicotine patch in Tourette's syndrome","volume":"4","author":"Silver","year":"1999","journal-title":"CNS Spectr"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0180","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4088\/JCP.v62n0908","article-title":"Transdermal nicotine and haloperidol in Tourette syndrome: a double-blind placebo controlled study","volume":"62","author":"Silver","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0185","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0022-3565(25)24880-7","article-title":"Rapid desensitization of the acute stimulatory effects of nicotine on rat plasma adrenocorticotropin and prolactin","volume":"238","author":"Sharp","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0190","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/BF02246040","article-title":"Acute tolerance to the locomotor stimulant effects of nicotine in the rat","volume":"104","author":"Hakan","year":"1991","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0195","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1098-2299(199607\/08)38:3\/4<231::AID-DDR12>3.0.CO;2-1","article-title":"Are nicotinic receptors activated or inhibited following chronic nicotine treatment?","volume":"38","author":"Collins","year":"1996","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0200","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/(SICI)1098-2299(199607\/08)38:3\/4<136::AID-DDR2>3.0.CO;2-N","article-title":"Regulation by nicotine of its own receptors","volume":"38","author":"Lukas","year":"1996","journal-title":"Drug Dev Res"},{"year":"2000","series-title":"Nicotinic therapeutics for Tourette syndrome and other neuropsychiatric disorders: from lab to clinic","author":"Shytle","key":"10.1016\/j.physbeh.2012.06.023_bb0205"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0210","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/(SICI)1098-2299(199607\/08)38:3\/4<290::AID-DDR18>3.0.CO;2-2","article-title":"Transdermal nicotine for Tourette's syndrome","volume":"38","author":"Shytle","year":"1996","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0215","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0149-2918(01)80059-X","article-title":"Mecamylamine: new therapeutic uses and toxicity\/risk profile","volume":"23","author":"Shytle","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0220","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/0091-3057(89)90061-0","article-title":"Mecamylamine increases nicotine preference and attenuates nicotine discrimination","volume":"32","author":"Rose","year":"1989","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0225","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/clpt.1994.105","article-title":"Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone","volume":"56","author":"Rose","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0230","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0893-133X(98)00076-1","article-title":"A nicotine antagonist, mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects [in process citation]","volume":"20","author":"Reid","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0235","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0014-2999(93)90434-J","article-title":"The mesolimbic dopamine-activating properties of ethanol are antagonized by mecamylamine","volume":"249","author":"Blomqvist","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0240","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0014-2999(97)01220-X","article-title":"Accumbal dopamine overflow after ethanol: localization of the antagonizing effect of mecamylamine","volume":"334","author":"Blomqvist","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0245","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0014-2999(96)00583-3","article-title":"Voluntary ethanol intake in the rat: effects of nicotinic acetylcholine receptor blockade or subchronic nicotine treatment","volume":"314","author":"Blomqvist","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0250","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(05)60822-7","article-title":"Treatment of Tourette's syndrome with mecamylamine [letter]","volume":"352","author":"Sanberg","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0255","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/cap.2000.10.59","article-title":"Mecamylamine in Tourette's syndrome: a two-year retrospective case study","volume":"10","author":"Silver","year":"2000","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0260","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0006-3223(00)00945-8","article-title":"Comorbid bipolar disorder in Tourette's syndrome responds to the nicotinic receptor antagonist mecamylamine (Inversine)","volume":"48","author":"Shytle","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0265","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/00004583-200109000-00020","article-title":"Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder","volume":"40","author":"Silver","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0270","first-page":"4S","article-title":"Potential mood stabilizing properties of nicotinic receptor antagonist, mecamylamine (Inversine (R))","volume":"49","author":"Shytle","year":"2001","journal-title":"Biol Psychiat"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0275","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/sj.mp.4001035","article-title":"Nicotinic acetylcholine receptors as targets for antidepressants","volume":"7","author":"Shytle","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0280","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/da.10035","article-title":"Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine","volume":"16","author":"Shytle","year":"2002","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0285","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00006842-197405000-00008","article-title":"Acetylcholine and depression","volume":"36","author":"Janowsky","year":"1974","journal-title":"Psychosom Med"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0290","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(72)93021-8","article-title":"A cholinergic\u2013adrenergic hypothesis of mania and depression","volume":"2","author":"Janowsky","year":"1972","journal-title":"Lancet"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0295","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archpsyc.62.10.1097","article-title":"Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"62","author":"Hasin","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0300","first-page":"26","article-title":"New approaches to the treatment of refractory depression","volume":"61","author":"Fava","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0305","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0149-2918(01)80059-X","article-title":"Mecamylamine: new therapeutic uses and safety profile","volume":"23","author":"Young","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0310","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/JCP.0b013e318172b49e","article-title":"Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study","volume":"28","author":"George","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0315","first-page":"A40","article-title":"Mecamylamine in the treatment of depressed patients who were inadequate responders to citalopram first-line therapy; a double-blind placebo controlled add-on study","volume":"21","author":"Dunbar","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0320","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1016\/S0024-3205(01)01338-8","article-title":"Nicotine induced seizures blocked by mecamylamine and its stereoisomers","volume":"69","author":"Newman","year":"2001","journal-title":"Life Sci"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0325","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0022-3565(24)29581-1","article-title":"Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes","volume":"297","author":"Papke","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0330","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1124\/jpet.108.146910","article-title":"Differential pharmacologies of mecamylamine enantiomers: positive allosteric modulation and noncompetitive inhibition","volume":"328","author":"Fedorov","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0335","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1755-5949.2008.00054.x","article-title":"TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity","volume":"14","author":"Lippiello","year":"2008","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0340","doi-asserted-by":"crossref","first-page":"S334-S","DOI":"10.1016\/S0924-977X(10)70458-2","article-title":"The potential of the nicotinic channel blocker TC-5214 as augmentation treatment in patients with major depression","volume":"20","author":"Dunbar","year":"2010","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0345","unstructured":"Dunbar, G. C. Positive effects of the nicotinic channel blocker TC-5214 as augmentation treatment in patients with major depressive disorder who are inadequate responders to a first-line SSRI nAChR2009 satellite meeting of the 39th annual meeting of the Society for Neuroscience. Chicago, IL2009."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0350","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1021\/cn100070s","article-title":"(S)-(+)-Mecamylamine (TC-5214): a neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for major depressive disorder (MDD)","volume":"1","author":"Lindsley","year":"2010","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0355","unstructured":"Sanberg, P. R., Shytle, R. D., Silver, A. A. Method of Treating Cognitive Deficits in Learning and Memory. U. S. Patent 6,979,698, awarded December 27, 2005."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0360","unstructured":"Shytle, D., Sanberg P. R., Newman, M., Silver, A. A. Exo-S-mecamylamine Formulation and Use in Treatment. U. S. Patent 6,734,215, awarded May 11, 2004."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0365","unstructured":"Sanberg, P. R., Shytle R. D., Silver, A. A. Nicotine Antagonists for Nicotine-Responsive Neuropsychiatric Disorders. U. S. Patent 6,034,079, awarded March 7, 2000."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0370","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1037\/0735-7044.102.5.748","article-title":"The catalepsy test: its ups and downs","volume":"102","author":"Sanberg","year":"1988","journal-title":"Behav Neurosci."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0375","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/BF00427696","article-title":"Parametric influences on catalepsy","volume":"82","author":"Sanberg","year":"1984","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0380","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF00427655","article-title":"Experimental influences on catalepsy","volume":"69","author":"Sanberg","year":"1980","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0385","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0014-2999(81)90054-6","article-title":"Kainic acid injections in the striatum alter the cataleptic and locomotor effects of drugs influencing dopaminergic and cholinergic systems","volume":"74","author":"Sanberg","year":"1981","journal-title":"Eur J Pharmacol."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0390","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1037\/0735-7036.97.1.59","article-title":"Dopaminergic and cholinergic influences on motor behavior in chickens","volume":"97","author":"Sanberg","year":"1983","journal-title":"J Comp Psychol."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0395","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00690925","article-title":"Haloperidol-induced emotional defecation: a possible model for neuroleptic anxiety syndrome","volume":"91","author":"Russell","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0400","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1037\/0735-7044.101.1.131","article-title":"The topography of amphetamine and scopolamine-induced hyperactivity: toward an activity print","volume":"101","author":"Sanberg","year":"1987","journal-title":"Behav Neurosci."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0405","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0006-8993(88)91584-3","article-title":"Quinolinic acid lesions of rat striatum abolish D1- and D2-dopamine-receptor-mediated catalepsy","volume":"450","author":"Calderon","year":"1988","journal-title":"Brain Research."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0410","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF00634453","article-title":"Neuroleptic-induced emotional defecation: effects of scopolamine and haloperidol","volume":"99","author":"Sanberg","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0415","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0031-9384(89)90256-4","article-title":"Neuroleptic-induced emotional defecation: effects of pimozide and apomorphine","volume":"46","author":"Sanberg","year":"1989","journal-title":"Physiol Behav."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0420","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1176\/ajp.146.3.411-a","article-title":"Underrecognized and underresearched side effects of neuroleptics","volume":"146","author":"Sanberg","year":"1989","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0425","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF00187264","article-title":"The effects of nicotine on locomotor behavior in non-tolerant rats: a multivariate assessment","volume":"93","author":"Jerome","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.physbeh.2012.06.023_bb0430","first-page":"385","article-title":"Nicotine potentiates the behavioral effects of haloperidol","volume":"27","author":"Emerich","year":"1991","journal-title":"Psychopharmacol Bull."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0435","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0091-3057(93)90357-Y","article-title":"Nicotine potentiation of haloperidol-induced catalepsy: striatal mechanisms","volume":"46","author":"Sanberg","year":"1993","journal-title":"Pharmacol Biochem Behav."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0440","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0091-3057(95)00119-H","article-title":"Nicotine enhances the learning and memory of aged rats","volume":"52","author":"Arendash","year":"1995","journal-title":"Pharmacol Biochem Behav."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0445","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/0197-4580(95)00091-R","article-title":"Nicotine enhances Morris water maze performance of young and aged rats","volume":"16","author":"Socci","year":"1995","journal-title":"Neurobiol Aging."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0450","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/0006-8993(94)01449-R","article-title":"Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21","volume":"674","author":"Arendash","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0455","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1006\/exnr.1995.1103","article-title":"(-)-nicotine protects against systemic kainic acid-induced excitotoxic effects","volume":"136","author":"Borlongan","year":"1995","journal-title":"Exp Neurol."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0460","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0893-133X(95)00080-W","article-title":"Nicotine blocks kainic acid-induced wet dog shakes in rats","volume":"13","author":"Shytle","year":"1995","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0465","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00008877-199911000-00017","article-title":"Locomotor behavioral effects of prenatal and postnatal nicotine exposure in rat offspring","volume":"10","author":"Newman","year":"1999","journal-title":"Behav Pharmacol."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0470","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1471-4159.2004.02347.x","article-title":"Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors","volume":"89","author":"Shytle","year":"2004","journal-title":"J Neurochem."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0475","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0278-5846(00)00178-0","article-title":"Corticosterone-attenuating and anxiolytic properties of mecamylamine in the rat","volume":"25","author":"Newman","year":"2001","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0480","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1037\/1064-1297.10.1.18","article-title":"Anxiolytic effects of mecamylamine in two animal models of anxiety","volume":"10","author":"Newman","year":"2002","journal-title":"Exp Clin Psychopharmacol."},{"key":"10.1016\/j.physbeh.2012.06.023_bb0485","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/00207450108986527","article-title":"Mecamylamine effects on haloperidol-induced catalepsy and defecation","volume":"109","author":"Sanberg","year":"2001","journal-title":"Int J Neurosci."}],"container-title":["Physiology &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031938412002478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031938412002478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T13:24:47Z","timestamp":1743686687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031938412002478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0031938412002478"],"URL":"https:\/\/doi.org\/10.1016\/j.physbeh.2012.06.023","relation":{},"ISSN":["0031-9384"],"issn-type":[{"type":"print","value":"0031-9384"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}